You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 163 No. 20, November 10, 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Controversies in Internal Medicine
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Nutrition/ Malnutrition
 •Gastroenterology
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Importance of Screening for Hemochromatosis

Suja Dubois, MD; Kris V. Kowdley, MD

Arch Intern Med. 2003;163:2424-2426.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

HEREDITARY HEMOCHROMATOSIS, commonly described as human leukocyte antigen–linked or HFE-associated hemochromatosis, is an inherited disorder of iron metabolism leading to excessive absorption of iron from the gastrointestinal tract.1 Patients with hemochromatosis may develop progressive iron loading in many parenchymal organs, resulting in cirrhosis complicated by liver failure or hepatocellular carcinoma, diabetes, arthropathy, and cardiac disease. Patients with cirrhosis associated with HH have a significantly increased risk of premature mortality. By contrast, patients diagnosed prior to the development of cirrhosis have a normal life expectancy when compared with age- and sex-matched controls.2 Therefore, population screening for HH has been advocated with the goal of identifying patients in the precirrhotic stage of the disease, particularly because noninvasive, sensitive, and specific screening tests are available and because iron depletion therapy is safe and can lead to improved outcomes. Furthermore, the identification of the HFE gene . . . [Full Text of this Article]

From the Division of Gastreonterology/ Hepatology, University of Washington School of Medicine, Seattle. The authors have no relevant financial interest in this article.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Hereditary Hemochromatosis and Its Elusive Natural History
Sharon M. McDonnell and R. Gibson Parrish
Arch Intern Med. 2003;163(20):2421-2423.
EXTRACT | FULL TEXT  

Rebuttal by Drs McDonnell and Parrish
Sharon M. McDonnell and R. Gibson Parrish
Arch Intern Med. 2003;163(20):2426.
EXTRACT | FULL TEXT  

Rebuttal by Drs Dubois and Kowdley
Suja Dubois and Kris V. Kowdley
Arch Intern Med. 2003;163(20):2427.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians
Schmitt et al.
ANN INTERN MED 2005;143:522-536.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.